亚太细胞与基因治疗生物製造市场：2022-2031

预计亚太细胞和基因治疗生物製造市场规模将从2022年的19.6亿美元成长到2031年的86亿美元，预测期内年复合成长率为17.88%。

由于已经过核准的治疗方法数量不断增加以及基础设施需求不断增加，预计该市场将会成长。此外，基因和细胞治疗适应症的不断扩大需要广泛的生物製造能力。

亚太地区的细胞和基因治疗生物製造业正进入快速扩张和变革的时期。由于已经过核准药品数量不断增加和基础设施需求不断增加，该地区有望成为尖端生物製造中心。基因和细胞治疗目标适应症的扩大推动了该地区对大型生物製造设施的巨大需求。由于政府、製药公司和学术机构的持续投资，帮助开发新的救命药物疗法，该市场也在不断增长。

本报告调查了亚太地区的细胞和基因治疗生物製造市场，提供了市场概况，分析了市场增长的各种影响因素、法律制度、市场规模趋势和预测以及各个细分市场和地区。/编译主要国家详细分析、竞争形势、主要企业分析等

主要市场统计数据
预测期	2022-2031
2022年评估	19.6亿美元
2031年预测	86亿美元
年复合成长率	17.88%

市场区隔：

细分 1：按产品类型

• 消耗品
• 装置
• 软体解决方案

细分 2：依最终用户划分

• 生命科学公司
• CRO
• CMO
• 细胞库

细分 3：按国家/地区

• 中国
• 日本
• 印度
• 韩国
• 澳洲/纽西兰
• 亚太地区其他地区

主要企业：

目录

第1章市场

• 产业展望
  • 市场概况与生态系统
  • 主要趋势
  • 机会评估
  • 法律规范
  • 产品基准评效
  • 专利分析
  • 商业模式分析
  • 研发线产品
  • 技术介绍矩阵
  • 资金筹措场景
  • 关键成功因素
• COVID-19 对细胞和基因治疗生物製造市场的影响
• 俄罗斯-乌克兰战争对细胞和基因治疗生物製造市场的影响

第2章亚太地区

• 亚太地区
  • 主要发现和机会评估
  • 市场动态
  • 市场规模/预测分析

第3章市场：竞争基准化分析/公司简介

• 竞争基准化分析
• 企业市场占有率分析
• 公司简介

“The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Expected to Reach $8.60 Billion by 2031.”

KEY MARKET STATISTICS
Forecast Period	2022 - 2031
2022 Evaluation	$1.96 Billion
2031 Forecast	$8.60 Billion
CAGR	17.88%

Introduction to Asia-Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market

The Asia Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market is expected to grow at a CAGR of 17.88% from $1.96 Billion in 2022 to $8.60 Billion in 2031 in the forecasted period of 2022-2031. APAC cell and gene therapy biomanufacturing industry is expected to grow due in part to the increasing number of authorized treatments and growing infrastructural requirements. Extensive biomanufacturing capabilities are also required due to the expanding target indications for gene and cell treatments.

Market Introduction

The industry for cell and gene therapy biomanufacturing in Asia-Pacific (APAC) is about to undergo a period of rapid expansion and change. This area is set to become a center for state-of-the-art biomanufacturing due to the rise of authorized medicines and the rising requirements for infrastructure. A significant need for large-scale biomanufacturing facilities in Asia-Pacific is being driven by the broadening range of target indications for gene and cell therapies. The APAC market for cell and gene therapy biomanufacturing is growing as a result of continued investment in this area by governments, pharmaceutical corporations, and academic organizations, which is helping to develop novel and perhaps life-saving medical therapies. In addition to seeing the creation of cutting-edge treatments, this area is essential to the world's biomanufacturing industry.

Market Segmentation:

Segmentation 1: by Product Type

• Consumables
• Equipment
• Software Solutions

Segmentation 2: by End User

• Life Science Companies
• Contract Research Organizations (CROs)
• Contract Manufacturing Organizations (CMOs)
• Cell Banks

Segmentation 3: by Country

• China
• Japan
• India
• South Korea
• Australia/New Zealand
• Rest-of-Asia-Pacific

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market:

• Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
• Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
• Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure

The market is expected to face some limitations as well due to the following challenges:

• High Set-Up Cost of Biomanufacturing Facilities

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions.

Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.

Competitive Strategy: Key players in the APAC cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Table of Contents

1 Markets

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
  • 1.1.2 Key Trends
    • 1.1.2.1 Biomanufacturing 4.0
    • 1.1.2.2 Growing Single-Use Technology Market Penetration
    • 1.1.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
    • 1.1.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
  • 1.1.3 Opportunity Assessment
  • 1.1.4 Regulatory Framework
  • 1.1.5 Product Benchmarking
    • 1.1.5.1 Product Benchmarking (by Product Type)
    • 1.1.5.2 Comparative Analysis (by Equipment)
  • 1.1.6 Patent Analysis
    • 1.1.6.1 Patent Analysis (by Year)
    • 1.1.6.2 Patent Analysis (by Country)
    • 1.1.6.3 Awaited Technologies
  • 1.1.7 Business Model Analysis
  • 1.1.8 Pipeline Products
  • 1.1.9 Technology Adoption Matrix
  • 1.1.10 Funding Scenario
  • 1.1.11 Key Success Factors
• 1.2 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
  • 1.2.1 Recommendations to Manufacturers
• 1.3 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2 Asia-Pacific

• 2.1 Asia-Pacific
  • 2.1.1 Key Findings and Opportunity Assessment
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Sizing and Forecast Analysis
    • 2.1.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 2.1.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 2.1.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 2.1.3.3.1 China
        • 2.1.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.2 Japan
        • 2.1.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.3 India
        • 2.1.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.4 South Korea
        • 2.1.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.5 Australia/New Zealand
        • 2.1.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.6 Rest-of-Asia-Pacific
        • 2.1.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)

3 Markets - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Competitive Landscape
    • 3.1.1.1 Segmental Growth Share Matrix
      • 3.1.1.1.1 Growth Share Analysis (by Product Type)
      • 3.1.1.1.2 Growth Share Analysis (by Application)
    • 3.1.1.2 Competitive Index (Unmet Needs and Innovations)
    • 3.1.1.3 Company Position Analysis
    • 3.1.1.4 Key Strategies and Developments
      • 3.1.1.4.1 Funding Activities
      • 3.1.1.4.2 New Offerings
      • 3.1.1.4.3 Mergers and Acquisitions
      • 3.1.1.4.4 Partnerships, Alliances, and Business Expansions
      • 3.1.1.4.5 Key Development Analysis
• 3.2 Company Share Analysis
• 3.3 Company Profiles
  • 3.3.1 WuXi AppTec
    • 3.3.1.1 Company Overview
    • 3.3.1.2 Role of WuXi AppTec in the Cell and Gene Therapy Biomanufacturing Market
    • 3.3.1.3 Major Product: Key Specifications
    • 3.3.1.4 Customers and Competitions/Opportunities
      • 3.3.1.4.1 Key Competitors
    • 3.3.1.5 Analyst Perspective

List of Figures

• Figure 1: Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 2: Cell and Gene Therapy Biomanufacturing Market: Drivers, Restraints, and Opportunities
• Figure 3: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Impact Analysis
• Figure 4: Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 5: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Region), $Billion, 2021 and 2031
• Figure 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Share of Key Developments and Strategies (by Category), January 2020-January 2023
• Figure 7: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Segmentation
• Figure 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market: Research Methodology
• Figure 9: Primary Research Methodology
• Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 11: Top-Down Approach (Segment-Wise Analysis)
• Figure 12: Market Overview and Ecosystem
• Figure 13: Insights on Strategies Adopted by Major Players, January 2020-January 2023
• Figure 14: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Trends, Market Shift, 2022-2031
• Figure 15: TcBuster vs. Viral Gene Engineering Technology, Comparative Analysis
• Figure 16: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Year), January 2020-December 2022
• Figure 17: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Country), January 2020-December 2022
• Figure 18: Anticipated Regulatory Milestones in 2023
• Figure 19: Anticipated Regulatory Approval, U.S. and EU, 2023
• Figure 20: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Technology Adoption Matrix
• Figure 21: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Success Factors
• Figure 22: Impact of COVID-19 on CGT Developmental Activities
• Figure 23: Progress in Cell and Gene Therapy (CGT) Regulation during COVID-19
• Figure 24: Ways to Increase Supply Chain and Manufacturing
• Figure 25: Impact on Biopharmaceutical Industries
• Figure 26: Cell and Gene Therapy Biomanufacturing Market Share (by Region)
• Figure 27: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
• Figure 28: Ongoing Clinical Trials, Asia-Pacific (by Country)
• Figure 29: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
• Figure 30: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 31: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 32: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
• Figure 33: China Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 34: China Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 35: China Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 36: Japan Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 37: Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 38: Japan Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 39: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, India, 2020 vs. 2040
• Figure 40: India Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 41: India Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 42: India Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 43: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, South Korea, 2020 vs. 2040
• Figure 44: South Korea Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 45: South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 46: South Korea Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 47: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 48: New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 49: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 50: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 51: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 52: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 53: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), 2021-2031
• Figure 54: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Application), 2021-2031
• Figure 55: Competitive Index, Unmet Needs, Solutions, and Impacts
• Figure 56: Company Position Analysis
• Figure 57: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Total Number of Key Developments, January 2020-January 2023
• Figure 58: Funding Activities, January 2020-January 2023
• Figure 59: New Offerings, January 2020-September 2023
• Figure 60: Mergers and Acquisitions, January 2020-January 2023
• Figure 61: Partnerships, Alliances, and Business Expansion Activities, January 2020-January 2023
• Figure 62: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Company Share Analysis, % Share, 2021
• Figure 63: WuXi AppTec: Product Portfolio

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Single-Use and Stainless-Steel Facilities, Comparative Analysis
• Table 3: Asia-Pacific Regulatory Scenario: Cell and Gene Therapy Biomanufacturing Market
• Table 4: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), Product Benchmarking
• Table 5: Comparative Analysis of Various Bioreactors Offered by Key Players
• Table 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Awaited Technologies
• Table 7: Business Models, Key Features
• Table 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
• Table 9: Approved Cell and Gene Therapies, Japan
• Table 10: Ongoing Industry Sponsored Cell and Gene Therapy Clinical Trials
• Table 11: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Development Analysis, January 2020-January 2023